Functional disability 5 years after acute respiratory distress syndrome
- PMID: 21470008
- DOI: 10.1056/NEJMoa1011802
Functional disability 5 years after acute respiratory distress syndrome
Abstract
Background: There have been few detailed, in-person interviews and examinations to obtain follow-up data on 5-year outcomes among survivors of the acute respiratory distress syndrome (ARDS).
Methods: We evaluated 109 survivors of ARDS at 3, 6, and 12 months and at 2, 3, 4, and 5 years after discharge from the intensive care unit. At each visit, patients were interviewed and examined; underwent pulmonary-function tests, the 6-minute walk test, resting and exercise oximetry, chest imaging, and a quality-of-life evaluation; and reported their use of health care services.
Results: At 5 years, the median 6-minute walk distance was 436 m (76% of predicted distance) and the Physical Component Score on the Medical Outcomes Study 36-Item Short-Form Health Survey was 41 (mean norm score matched for age and sex, 50). With respect to this score, younger patients had a greater rate of recovery than older patients, but neither group returned to normal predicted levels of physical function at 5 years. Pulmonary function was normal to near-normal. A constellation of other physical and psychological problems developed or persisted in patients and family caregivers for up to 5 years. Patients with more coexisting illnesses incurred greater 5-year costs.
Conclusions: Exercise limitation, physical and psychological sequelae, decreased physical quality of life, and increased costs and use of health care services are important legacies of severe lung injury.
Comment in
-
The burden of functional recovery from ARDS.N Engl J Med. 2011 Apr 7;364(14):1358-9. doi: 10.1056/NEJMe1101057. N Engl J Med. 2011. PMID: 21470014 No abstract available.
-
Functional disability 5 years after ARDS.N Engl J Med. 2011 Jul 21;365(3):275; author reply 275-6. doi: 10.1056/NEJMc1105509. N Engl J Med. 2011. PMID: 21774724 No abstract available.
-
Functional disability 5 years after ARDS.N Engl J Med. 2011 Jul 21;365(3):274-5; author reply 275-6. doi: 10.1056/NEJMc1105509. N Engl J Med. 2011. PMID: 21774725 No abstract available.
Similar articles
-
Recovery and long-term outcome in acute respiratory distress syndrome.Crit Care Clin. 2011 Jul;27(3):685-704. doi: 10.1016/j.ccc.2011.04.003. Crit Care Clin. 2011. PMID: 21742223 Review.
-
Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome.Am J Respir Crit Care Med. 2005 Feb 15;171(4):340-7. doi: 10.1164/rccm.200406-763OC. Epub 2004 Nov 12. Am J Respir Crit Care Med. 2005. PMID: 15542793
-
The burden of functional recovery from ARDS.N Engl J Med. 2011 Apr 7;364(14):1358-9. doi: 10.1056/NEJMe1101057. N Engl J Med. 2011. PMID: 21470014 No abstract available.
-
ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and function and health-related quality of life.Acta Anaesthesiol Scand. 2009 Apr;53(4):489-95. doi: 10.1111/j.1399-6576.2008.01808.x. Epub 2009 Feb 18. Acta Anaesthesiol Scand. 2009. PMID: 19226296
-
Long-term outcomes in patients surviving acute respiratory distress syndrome.Semin Respir Crit Care Med. 2010 Feb;31(1):55-65. doi: 10.1055/s-0029-1246285. Epub 2010 Jan 25. Semin Respir Crit Care Med. 2010. PMID: 20101548 Review.
Cited by
-
Effect of long-term rehabilitation on takotsubo syndrome-induced severe intensive care unit-acquired weakness: a case report.J Phys Ther Sci. 2024 Nov;36(11):750-755. doi: 10.1589/jpts.36.750. Epub 2024 Nov 1. J Phys Ther Sci. 2024. PMID: 39493685 Free PMC article.
-
Persistent Fatigue, Weakness, and Aberrant Muscle Mitochondria in Survivors of Critical COVID-19.Crit Care Explor. 2024 Oct 16;6(10):e1164. doi: 10.1097/CCE.0000000000001164. eCollection 2024 Oct 1. Crit Care Explor. 2024. PMID: 39412208 Free PMC article.
-
Long-term lung function recovery after ECMO versus non-ECMO management in acute respiratory failure: a systematic review and meta-analysis.BMC Pulm Med. 2024 Oct 10;24(1):504. doi: 10.1186/s12890-024-03321-1. BMC Pulm Med. 2024. PMID: 39390464 Free PMC article.
-
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis.Pharmacoeconomics. 2024 Oct 10. doi: 10.1007/s40273-024-01436-1. Online ahead of print. Pharmacoeconomics. 2024. PMID: 39388034
-
Shh Signaling from the Injured Lung Microenvironment Drives BMSCs Differentiation into Alveolar Type II Cells for Acute Lung Injury Treatment in Mice.Stem Cells Int. 2024 Sep 28;2024:1823163. doi: 10.1155/2024/1823163. eCollection 2024. Stem Cells Int. 2024. PMID: 39372681 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical